You are in: eMedicine Specialties > Ophthalmology > CHOROID Choroidal DetachmentArticle Last Updated: Sep 11, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Carlo E Traverso, MD, Associate Professor, University Eye Clinic, Genova; Consulting Staff and Head of Glaucoma and Cornea Clinical Unit, University of Genova Medical School, Italy Carlo E Traverso is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, and European Glaucoma Society Editors: Richard W Allinson, MD, Associate Professor, Division of Ophthalmology, Texas A&M University Health Science Center, Associate Professor, Department of Surgery, Scott and White Clinic; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Steve Charles, MD, Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine; Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri; Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences Author and Editor Disclosure Synonyms and related keywords: serous choroidal detachment, choroidals, choroidal effusion, delayed suprachoroidal hemorrhage, nonexpulsive suprachoroidal hemorrhage, hemorrhagic choroidal detachment, expulsive hemorrhage, intraoperative choroidal detachment/hemorrhage, choroidal vascular plexus INTRODUCTIONBackgroundThe suprachoroidal space is normally virtual because the choroid is in close apposition to the sclera. As fluid accumulates, this space becomes real, and the choroid is displaced from its normal position. Fluid accumulation, either serumlike or blood, also can occur within the choroid, which is a spongy tissue. Serous choroidal detachment involves transudation of serum into the suprachoroidal space. This transudation may be due to increased transmural pressure, most frequently caused by globe hypotony of any etiology or trauma, or exudation of serum, most frequently caused by inflammation. Hemorrhagic choroidal detachment is a hemorrhage in the suprachoroidal space or within the choroid caused by the rupture of choroidal vessels. This can occur spontaneously (rare), as a consequence of ocular trauma, during eye surgery, or after eye surgery. Except for posttraumatic cases, the clinical picture is very similar in all forms of choroidal detachment, the only difference being the time of presentation. The outcome is generally worse for intraoperative hemorrhages, which often are accompanied by loss of eye contents. PathophysiologyThe exact triggering mechanism is unknown. An increase in transmural pressure in the choroidal vascular plexus can be caused by elevated blood pressure, low intraocular pressure (IOP), or a combination. An increase in vascular permeability is caused by inflammation. The consequence is passage of serum, with large protein molecules into the suprachoroidal space. Since the protein content of the fluid accumulating in the normally virtual suprachoroidal space is similar to plasma with an equal oncotic pressure, its spontaneous reabsorption is unlikely, unless the underlying cause (ie, inflammation, hypotony) is treated. A breakdown of the blood-aqueous barrier across the pigmented epithelium may cause a superimposed nonrhegmatogenous retinal detachment. As a sequela, linear areas of pigmented epithelium hypertrophy, called Verhoeff streaks, indicate the posterior limits of the retinal detachment after its reabsorption. FrequencyInternationalSerous choroidal detachments are recognized easily when large. More subtle, anterior, shallow ciliochoroidal detachments, although relatively common after glaucoma filtration surgery, are undetected or unreported. Suprachoroidal hemorrhage is a rare occurrence. Reported data vary between 0.05-6%, depending on the sample. See Causes for predisposing factors. Mortality/MorbidityNo mortality has been reported. Morbidity in serous choroidal detachment is significant. In phakic eyes, lens opacities can progress rapidly. Cyclitic pupillary membranes may develop. When a flat chamber is present, corneal endothelial damage and peripheral anterior synechiae can occur. Chronic choroidal detachment can lead to maculopathy and globe phthisis. In hemorrhagic detachment, morbidity is the same as for serous detachment, but the prognosis is worse. Loss of useful vision is reported in up to 40% of cases. RaceNo racial predilection exists. SexNo sexual predilection exists. AgeHemorrhagic detachments are seen more often in elderly patients. CLINICALHistory
Physical
Causes
DIFFERENTIALSGlaucoma, Malignant Melanoma, Choroidal Pupillary Block, Aphakic Pupillary Block, Pseudophakic Retinal Detachment, Exudative Retinal Detachment, Postoperative Retinal Detachment, Tractional
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Cyclopentolate hydrochloride 1% (AK-Pentolate, Cyclogyl, I-Pentolate) |
|---|---|
| Description | Blocks muscle of ciliary body and sphincter muscle of iris from responding to cholinergic stimulation, thus causing mydriasis and cycloplegia. Induces mydriasis in 30-60 min and cycloplegia in 25-75 min. These effects last up to 24 h. |
| Adult Dose | 1 gtt of 1% solution usually adequate to induce cycloplegia; if necessary, repeat in 5-10 min |
| Pediatric Dose | <1 year: 1 gtt of 0.5% solution with digital pressure on lacrimal sac >1 year: 1 gtt of 0.5%, 1%, or 2% solution to induce cycloplegia; if necessary, repeat in 5-10 min |
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma |
| Interactions | Decreases effects of carbachol and cholinesterase inhibitors |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in patients (eg, elderly) where increased IOP may be present; can cause toxic anticholinergic systemic adverse effects (common in children, especially infants) but incidence rare when used sparingly; compressing lacrimal sac by digital pressure for 1-3 min, following application, may minimize systemic absorption; skin rash, abdominal distension in infants, tachycardia, vasodilation, urinary retention, diminished GI motility, decreased secretion in salivary and sweat glands, pharynx, bronchi, and nose may occur |
| Drug Name | Atropine sulfate 1% (Isopto, Atropair, Atropisol) |
|---|---|
| Description | Acts at parasympathetic sites in smooth muscle to block response of sphincter muscle of iris and muscle of ciliary body to acetylcholine, causing mydriasis and cycloplegia. |
| Adult Dose | Solution (1%): 1-2 gtt in affected eye(s) qid; compress lacrimal sac by digital pressure for 1-3 min after instillation Ointment: Apply 0.5-inch ribbon in conjunctival sac tid |
| Pediatric Dose | Solution (0.5%): 1-2 gtt in affected eye(s) bid/tid Ointment: Not established |
| Contraindications | Documented hypersensitivity; thyrotoxicosis; narrow angle glaucoma; tachycardia |
| Interactions | Coadministration with other anticholinergics have additive effects; pharmacologic effects of atenolol and digoxin may increase with atropine; antipsychotic effects of phenothiazines may decrease; tricyclic antidepressants with anticholinergic activity may increase effects of atropine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Extreme caution in infants and children; excessive use in children and certain susceptible individuals may produce general toxic symptoms, including CNS disturbances, respiratory depression, and hypotension; coma and death reported in infants; caution in patients with Down syndrome and/or children with brain damage to prevent hyperreactive response; caution in coronary heart disease, tachycardia, congestive heart failure, cardiac arrhythmias, and hypertension; caution in peritonitis, ulcerative colitis, hepatic disease, and hiatal hernia with reflux esophagitis; in prostatic hypertrophy, prostatism can have dysuria and may require catheterization; prolonged local administration can cause vascular congestion, follicular conjunctivitis, exudates, edema, and eczematoid dermatitis |
Instillation of a long-acting cycloplegic agent relaxes any ciliary muscle spasm that causes a deep aching pain and photophobia.
| Drug Name | Tropicamide 1% (Mydriacyl, Tropicacyl) |
|---|---|
| Description | Blocks sphincter muscle of iris and muscle of ciliary body from responding to cholinergic stimulation. |
| Adult Dose | Cycloplegia: 2 gtt in affected eye(s); may repeat in 5 min Mydriasis: 1-2 gtt in affected eye(s) 15-20 min before examination; may repeat q30min prn |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | CNS disturbances, psychotic reactions, behavioral disturbances, and cardiorespiratory collapse (especially in infants) may occur; adverse effects include transient stinging, blurred vision, mouth dryness, photophobia with or without corneal staining, tachycardia, parasympathetic stimulation, headache, and allergic reactions |
Have both anti-inflammatory (glucocorticoid) and salt-retaining (mineralocorticoid) properties. Glucocorticoids have profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.
| Drug Name | Prednisone (Deltasone, Orasone, Meticorten) |
|---|---|
| Description | May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. |
| Adult Dose | 5-60 mg/d PO qd or divided bid/qid; taper over 2 wk as symptoms resolve |
| Pediatric Dose | 4-5 mg/m2/d PO; alternatively, 0.05-2 mg/kg PO divided bid/qid; taper over 2 wk as symptoms resolve |
| Contraindications | Documented hypersensitivity; viral infection; peptic ulcer disease; hepatic dysfunction; connective tissue infections; fungal or tubercular skin infections; GI disease |
| Interactions | Coadministration with estrogens may decrease prednisone clearance; concurrent use with digoxin may cause digitalis toxicity secondary to hypokalemia; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections may occur with glucocorticoid use |
| Drug Name | Prednisolone (AK-Pred, Econopred, Inflamase Forte) |
|---|---|
| Description | Decreases inflammation and corneal neovascularization. Suppresses migration of polymorphonuclear leukocytes and reverses increased capillary permeability. In cases of bacterial infections, concomitant use of anti-infective agents is mandatory; if signs and symptoms do not improve after 2 days, reevaluate patient. Dosing may be reduced, but advise patients not to discontinue therapy prematurely. |
| Adult Dose | Solution: 1-2 gtt in conjunctival sac q1h during day and q2h noct; once desired response is obtained, 1 gtt q4h; may reduce to 1 gtt tid/qid to control symptoms Suspension: Shake well before using; 1-2 gtt in conjunctival sac 2-4 times/d; if necessary, may increase dosing frequency during initial 24-48 h |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; viral, fungal, or tubercular infections |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in hypertension; known to cause cataract formation with long-term use; suspect fungal invasion in any persistent corneal ulceration where a corticosteroid has been used or is in use (obtain fungal cultures when appropriate) |
| Media file 1: Serous choroidal detachment. Two lobes (ie, supertemporal, supranasal) of fluid accumulation are visible. The choroidal folds seen at the posterior pole are due to concomitant hypotony. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: B-scan ultrasonography examination of choroidal detachment. Fluid appears to be serum on one side (upper) and blood on the other side (below). Retina-to-retina contact, or kissing choroidal detachment, is present. | |
![]() | View Full Size Image | Media type: Image |
| Media file 3: Kissing choroidal detachment. When the lobes of the detachment are sufficiently large, retina-to-retina contact occurs. If this is extended centrally, the clinical picture is described as kissing choroidals. The extension of the lobes of detachment/edema is important for the decision-making process regarding the clinical management. | |
![]() | View Full Size Image | Media type: Image |
| Media file 4: Postoperative suprachoroidal hemorrhage. In this buphthalmic aphakic eye, suprachoroidal hemorrhage resulted in vitreous hemorrhage, retinal detachment, and extrusion of retina and blood through the pupil into the anterior chamber. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 5: Drainage of suprachoroidal space. After the posterior sclerostomies are performed, gentle infusion in the anterior chamber through a paracentesis tract helps the globe to maintain a tone while the fluid exit from the suprachoroidal space is facilitated. | |
![]() | View Full Size Image | Media type: Image |
| Media file 6: Drainage of suprachoroidal space. The hemorrhagic fluid is darker than fresh blood. Mechanical gaping of the radial incisions facilitates the egress of fluid. | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Sep 11, 2007